Global IP Holdings v. GVB Biopharma

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Global IP Holdings, LLC (California)
  • Defendant: GVB Biopharma (Colorado)
  • Plaintiff's Counsel: DNL Zito
• Case Identification: 1:25-cv-01996, D. Colo., 06/27/2027
• Venue Allegations: The complaint does not explicitly state the basis for venue, but Defendant GVB Biopharma is identified with a principal place of business in Denver, Colorado, which is within the District of Colorado.
• Core Dispute: Plaintiff alleges that Defendant's production process for cannabinoid and terpene extracts infringes patents related to methods of cold-temperature solvent extraction designed to reduce the co-extraction of undesirable compounds like chlorophyll.
• Technical Context: The technology concerns purification methods for cannabis and hemp extracts, a critical process for producing high-quality isolates for the pharmaceutical, nutraceutical, and consumer goods markets.
• Key Procedural History: Plaintiff filed a Notice of Errata to correct the name of the defendant and a non-party reference in the original complaint. The patents-in-suit are related, with U.S. Patent No. 10,814,248 being a continuation-in-part of the application that led to U.S. Patent No. 10,507,407. A Certificate of Correction was issued for the '407 Patent, clarifying language in Claim 1. The '248 Patent was issued with a terminal disclaimer.

Case Timeline

Date	Event
2016-04-14	Earliest Priority Date ('407 & '248 Patents)
2019-12-17	'407 Patent Issue Date
2020-10-27	'248 Patent Issue Date
2023-03-28	'407 Patent Certificate of Correction Issue Date
2025-10-27	Complaint Errata Filing Date
2027-06-27	Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,507,407 - METHODS TO REDUCE CHLOROPHYLL CO-EXTRACTION THROUGH EXTRACTION OF SELECT MOIETIES ESSENTIAL OILS AND AROMATIC ISOLATES (Issued Dec. 17, 2019)

The Invention Explained

• Problem Addressed: The patent's background describes the drawbacks of conventional methods for extracting cannabinoids and terpenes from plants like hemp. These methods, including hydrocarbon-based, lipid-based, and supercritical CO2 extraction, are described as suffering from issues such as safety hazards, high costs, and the co-extraction of undesirable compounds like plant lipids and chlorophyll, which then require costly and complex post-extraction purification steps '407 Patent, col. 1:21-44
• The Patented Solution: The invention proposes a method using a super-cooled solvent, specifically 100% grain ethanol, to solve this problem '407 Patent, col. 2:4-5 By chilling both the plant substrate and the solvent to a specific low-temperature range (e.g., -30°C to -50°C) before and during extraction, the process selectively extracts the desired moieties (cannabinoids, terpenes) while leaving the undesirable, less-soluble lipids and chlorophyll behind in the plant material '407 Patent, abstract '407 Patent, col. 2:6-15 The system is depicted in diagrams showing the arrangement of vessels and plumbing designed to operate at these ultra-low temperatures '407 Patent, FIG. 1
• Technical Importance: This approach provided a method to produce a cleaner, purer cannabinoid extract with minimal post-processing, which is highly valuable for commercial-scale manufacturing where product purity and process efficiency are paramount '407 Patent, col. 2:58-62

Key Claims at a Glance

• The complaint asserts at least independent claim 1 Corrected Compl. ¶19
• The essential elements of independent claim 1, as corrected by the Certificate of Correction, include:
  • (i) a pre-processing step of lowering a solvent's temperature to a range of -30°C to -50°C;
  • (ii) contacting the plant substrate with the solvent at a temperature between -30°C to -50°C to create an emulsion;
  • (iii) evaporating the emulsion via atmospheric evaporation;
  • (iv) recovering the solvent from the emulsion; and
  • (v) purging the resulting extract so it is "substantially free of any lipids and chlorophyll."
• The complaint does not explicitly reserve the right to assert dependent claims.

U.S. Patent No. 10,814,248 - METHODS TO REDUCE CHLOROPHYLL CO-EXTRACTION THROUGH EXTRACTION OF SELECT MOIETIES ESSENTIAL OILS AND AROMATIC ISOLATES (Issued Oct. 27, 2020)

The Invention Explained

• Problem Addressed: Like its parent patent, the '248 Patent addresses the need for a safer, more reliable, and more efficient process for extracting cannabinoids from plant matter that avoids the co-extraction of lipids and chlorophyll common in prior art methods '248 Patent, col. 1:47-58
• The Patented Solution: The '248 Patent claims a similar cold extraction process but explicitly excludes the use of liquid carbon dioxide and introduces claims covering specific solvent mixtures '248 Patent, claim 1 The method again relies on contacting a plant substrate with a solvent at a temperature range of -30°C to -50°C '248 Patent, claim 1 The specification provides extensive detail on alternative non-ethanol solvents and various mixture ratios, such as 95% ethanol plus 5% of a non-ethanol solvent, that can be used in the process '248 Patent, col. 3:26-51
• Technical Importance: This patent appears to broaden the scope of protection around the core cold-extraction technology by claiming specific alternative solvent formulations and explicitly carving out certain technologies, thereby refining the invention for different commercial applications '248 Patent, col. 2:56-64

Key Claims at a Glance

• The complaint asserts at least independent claim 1 Corrected Compl. ¶19
• The essential elements of independent claim 1 include:
  • Excluding the use of liquid carbon dioxide;
  • (i) a pre-processing step of lowering a solvent's temperature to a range of -30°C to -50°C;
  • (ii) contacting the cannabis or hemp plant substrate with the solvent at a temperature of -30°C to -50°C;
  • (iii) evaporating the resulting emulsion;
  • (iv) recovering the solvent;
  • (v) purging under vacuum, whereby the resulting extract is "substantially free of any lipids and chlorophyll"; and
  • Optional solvent compositions, including (a) 95% ethanol and 5% of "a solvent that is another solvent that does not comprise ethanol," or (b) a solvent from the group of heptane, hexane, isopropyl alcohol, and methanol.
• The complaint does not explicitly reserve the right to assert dependent claims.

III. The Accused Instrumentality

Product Identification

The accused instrumentality is the "production process used by GVB" Biopharma Corrected Compl. ¶19

Functionality and Market Context

The complaint errata alleges that the defendant, GVB Biopharma, utilizes a production process that practices the claims of the '407 and '248 patents Corrected Compl. ¶19 The errata references, but does not include, claim charts that purportedly "describe the production process used by GVB" Corrected Compl. ¶19 Without these charts or further description, the specific functionalities of GVB's process cannot be analyzed beyond the allegation that they map onto the elements of the asserted patent claims. The complaint does not provide sufficient detail for analysis of the accused process's commercial importance or market positioning.

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint errata references claim charts that were attached to the original complaint but were not provided for this analysis Corrected Compl. ¶19 The narrative theory of infringement is that the defendant's production process meets, element-by-element, the limitations of the asserted claims of the patents-in-suit Corrected Compl. ¶19 The analysis below summarizes this theory by mapping the elements of the representative independent claims to the alleged, but undescribed, functionalities of the accused process.

'407 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
(i) pre-processing comprising lowering the temperature of a solvent to a range of -30 degrees C. and -50 degrees C.	Defendant's process is alleged to involve chilling a solvent to a temperature within the claimed -30°C to -50°C range before extraction.	¶19	col. 8:16-18
(ii) contacting at -30 degrees C. to -50 degrees C. wherein there is a contacting time between the plant substrate and the solvent to create an emulsion	Defendant's process is alleged to involve contacting a plant substrate with the chilled solvent at a temperature within the claimed range to create an emulsion.	¶19	col. 8:19-22
(iii) evaporating for reduction of the emulsion by means of atmospheric evaporation of the solvent	Defendant's process is alleged to include a step of reducing the emulsion via atmospheric evaporation.	¶19	col. 8:23-25
(iv) recovering for recovery of the solvent from the emulsion	Defendant's process is alleged to include a step for recovering the solvent from the emulsion.	¶19	col. 8:26-27
(v) purging whereby a resultory extract is substantially free of any lipids and chlorophyll.	Defendant's process is alleged to include a purging step that results in an extract that is substantially free of lipids and chlorophyll.	¶19	col. 8:28-30

'248 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A safer and more reliable extraction process... wherein the process excludes use of liquid carbon dioxide	Defendant's process is alleged to be a safer and more reliable extraction method that does not use liquid carbon dioxide.	¶19	col. 24:1-6
(i) pre-processing comprising lowering the temperature of a solvent to a range of -30 degrees C. to -50 degrees C.	Defendant's process is alleged to involve chilling a solvent to a temperature within the claimed -30°C to -50°C range.	¶19	col. 24:7-9
(ii) contacting at -30 degrees C. to -50 degrees C., wherein there is a contacting time between the cannabis plant substrate and the solvent to create an emulsion	Defendant's process is alleged to involve contacting a cannabis or hemp substrate with the chilled solvent within the claimed temperature range.	¶19	col. 24:10-13
(v) purging under vacuum to remove remaining solvent from the extract whereby a resu tory extract is substantially free of any lipids and chlorophyll	Defendant's process is alleged to include a vacuum purging step that results in an extract that is substantially free of lipids and chlorophyll.	¶19	col. 24:17-21

• Identified Points of Contention:
  • Factual Questions: A primary point of contention will be factual: does the Defendant's process actually operate within the specific temperature ranges (e.g., -30°C to -50°C) required by the claims? The case may turn on evidence such as batch records, standard operating procedures, and expert testimony concerning the temperatures used in GVB's process.
  • Scope Questions: The case raises the question of whether the output of the Defendant's process meets the functional limitation of being "substantially free of any lipids and chlorophyll." The parties may dispute the quantitative threshold required to satisfy this limitation.

V. Key Claim Terms for Construction

• Term 1: "substantially free of any lipids and chlorophyll" (from '407 Patent, claim 1; '248 Patent, claim 1)

  • Context and Importance: This term defines the required quality of the final product. Its construction is critical because infringement will depend on whether the defendant's final extract meets this level of purity. Practitioners may focus on this term because it is a functional, qualitative limitation that lacks a precise numerical definition in the claim itself, making it a likely subject of dispute.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The body of the specification discusses the goal of bypassing "undesired constituents" generally, which could support a more flexible, qualitative interpretation of "substantially free" rather than a strict numerical limit '407 Patent, col. 1:26-29
    • Evidence for a Narrower Interpretation: The abstract of both patents explicitly states that the methods provide an extract "with a concentration of chlorophyll that is below 1%" '407 Patent, abstract '248 Patent, abstract A party may argue that this language serves to define and limit the scope of "substantially free" to a specific, measurable percentage.

• Term 2: "a solvent that is another solvent that does not comprise ethanol" (from '248 Patent, claim 1)

  • Context and Importance: This term appears in an optional limitation describing a specific solvent mixture (95% ethanol and 5% of this "another solvent"). The construction of this phrase is important for determining whether processes using complex solvent blends, rather than a simple two-part mixture, fall within the claim's scope.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification discloses a wide array of "non-ethanol solvents" that can be used, including mixtures, which could support an interpretation that "another solvent" can itself be a mixture of multiple chemical compounds '248 Patent, col. 5:6-32
    • Evidence for a Narrower Interpretation: The use of the singular articles "a" and "another" in the claim language could support an argument that the 5% component must be a single, distinct non-ethanol solvent, not a pre-existing mixture of solvents. The specification's long list of individual candidate solvents may be cited to bolster this narrower reading '248 Patent, col. 5:12-32

VI. Other Allegations

The provided complaint errata does not contain sufficient detail for analysis of indirect or willful infringement.

VII. Analyst's Conclusion: Key Questions for the Case

1. A core issue will be one of definitional scope: can the qualitative claim term "substantially free of any lipids and chlorophyll" be limited to the quantitative "below 1%" threshold mentioned in the patents' abstracts, or will it be given a broader, more functional meaning by the court? The answer will directly impact the evidence required to prove or disprove infringement.
2. A key evidentiary question will be one of process verification: what evidence will the Plaintiff present to demonstrate that the Defendant's commercial production process consistently operates within the specific, and relatively narrow, temperature range of -30°C to -50°C as mandated by the asserted claims?
3. The analysis of infringement of the '248 Patent may turn on a question of compositional scope: does the phrase "a solvent that is another solvent that does not comprise ethanol" read on a mixture of multiple non-ethanol solvents, or is it limited to a single non-ethanol solvent? This will be critical if the accused process uses a complex solvent blend.